LILLY-14X-IE-JFCC

Study Sponsor: Lilly

Study Title

A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (SQUIRE)

Medicine or Vaccine (generic name)

Necitumumab

Sponsor Identification Number

14X-IE-JFCC

Trial Registry Identification Number(#'s)

NCT00981058

Medical Condition

Squamous Non-Small Cell Lung Cancer

Phase

Phase 3

Link to study details on the Lilly Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

https://clinicaltrials.gov/ct2/show/NCT00981058?term=jfcc&rank=1

Link to study details on EudraCT (if available)

Not available

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

December 2016